Loading...
Risk of Reverse Seroconversion of Hepatitis B Virus Surface Antigen in Rituximab-Treated Non-Hodgkin Lymphoma Patients: A Large Cohort Retrospective Study
Rituximab causes hepatitis B virus (HBV) reactivation in HBV surface antigen (HBsAg)-seronegative patients with CD20-positive B-cell non-Hodgkin lymphoma (CD20(+) NHL), especially for those seropositive to the antibody of core antigen (anti-HBc). Clinical hepatitis usually develops after reverse ser...
Na minha lista:
| Udgivet i: | Medicine (Baltimore) |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Wolters Kluwer Health
2015
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4616669/ https://ncbi.nlm.nih.gov/pubmed/26266374 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000001321 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|